Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

Rucaparib

Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.

Trial Locations (23)

22004

Hospital General San Jorge, Huesca

28027

Clínica Universidad de Navarra, Madrid

28033

MD Anderson Cancer Center, Madrid

28040

Hospital Clínico San Carlos, Madrid

Hospital Universitario Fundación Jiménez Díaz, Madrid

28041

Hospital Universitario 12 Octubre, Madrid

28050

Centro Integral Oncológico Clara Campal, Madrid

28702

Hospital Universitario Infanta Sofía, San Sebastián de los Reyes

28942

Hospital Universitario de Fuenlabrada, Fuenlabrada

29010

Hospital Universitario Virgen de la Victoria, Málaga

36071

Complejo Hospitalario Universitario de Pontevedra, Pontevedra

41013

Hospital Universitario Virgen del Rocío, Seville

41014

Hospital Universitario Nuestra Señora de Valme, Seville

46009

Instituto Valenciano De Oncologia, Valencia

46026

Hospital Universitari i Politecnic La Fe, Valencia

46800

Hospital Público Lluis Alcanyis, Xàtiva

50009

Hospital Clínico Universitario Lozano Blesa, Zaragoza

Hospital Universitario Miguel Servet, Zaragoza

04009

Hospital Torrecárdenas, Almería

07120

Hospital Universitario Son Espases, Palma de Mallorca

08003

Hospital del Mar, Barcelona

08036

Hospital Clínic i Provincial, Barcelona

01009

Hospital Universitario de Araba Txagorritxu, Vitoria-Gasteiz

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

Grupo Español de Investigación en Cáncer de Ovario

OTHER